uniQure Eyes Q3 2026 Filing for HD Gene Therapy; 4-Year Data in Sept

For biotech professionals, the imminent regulatory filing for uniQure's AMT-130 marks a potential turning point for Huntington's disease treatment—a condition with no disease-modifying therapy. With pivotal data in hand and a clear path to approval, uniQure's progress highlights the real-world impact of gene therapy pipelines, offering a model for other rare disease programs.

A slate of upcoming clinical and regulatory catalysts is about to test the durability of recent big gains among five biotech companies highlighted by RTTNews: uniQure (QURE), CareDx (CDNA), Adaptive Biotechnologies (ADPT), Enliven Therapeutics (ELVN), and Amylyx Pharmaceuticals (AMLX). At the forefront is uniQure, a gene therapy pioneer whose lead candidate, AMT-130 for Huntington’s disease, is on the cusp of a regulatory filing that could reshape the standard of care for this devastating neurological condition. The company’s pipeline, which also includes programs for Fabry disease and refractory mesial temporal lobe epilepsy, is advancing rapidly, underscored by a series of positive data readouts in the first half of 2026. With regulatory submissions planned for the U.S. and U.K. in the third quarter of 2026 and four-year follow-up data from the pivotal phase I/II study expected in September, uniQure is a textbook example of how clinical milestones can drive biotech valuation.

“

For biotech professionals, the imminent regulatory filing for uniQure's AMT-130 marks a potential turning point for Huntington's disease treatment—a condition with no disease-modifying therapy.

The context for this cluster is a market environment where small- and mid-cap biotech names often swing violently on binary events. The RTTNews piece explicitly notes these five stocks “delivered big gains,” implying that recent quarterly or trial-related news has already rewarded shareholders. For uniQure, the foundational event was the September 2025 release of positive topline data from the pivotal phase I/II study of AMT-130, an AAV5-based gene therapy designed to stop or slow Huntington’s disease progression by silencing the mutant huntingtin gene. That data showed statistically significant improvements in disease markers and functional outcomes, sending the stock sharply higher. Since then, the company has steadily de-risked its pipeline: updated phase I/II data for AMT-191 in Fabry disease in February 2026 confirmed durable enzyme activity, and June 2026 brought not only more detailed analyses of that Fabry program but also the first preliminary safety and exploratory efficacy signals from the low-dose cohort of the ongoing phase I/IIa trial of AMT-260 in refractory mesial temporal lobe epilepsy. These data points have not only solidified conviction in uniQure’s gene therapy platform but also highlighted the company’s ability to retain global manufacturing rights for its licensed product HEMGENIX—the world’s first approved gene therapy for hemophilia B, commercialized by CSL Behring—providing a revenue backstop and manufacturing expertise.

From an industry perspective, the approaching regulatory filing for AMT-130 is a milestone with broad implications. Huntington’s disease remains a high-unmet-need indication with no disease-modifying treatment; a gene therapy that can be administered once and provide lasting effect would be a paradigm shift. The planned Q3 2026 submission will likely be based on the September 2025 data and will test regulators’ willingness to accept a single-arm, open-label phase I/II dataset for an accelerated approval. The U.K.’s MHRA could serve as an initial approval gateway, with the U.S. FDA potentially following. Simultaneously, the four-year data expected in September 2026 will reveal the durability of AMT-130’s therapeutic response, a critical factor in both regulatory assessment and payer adoption. Other gene therapy companies, such as Spark Therapeutics (now part of Roche) and Voyager Therapeutics, are watching closely, as uniQure’s success could de-risk the entire AAV-based CNS gene therapy field.

While uniQure provides the most detailed catalyst map from the available sources, the other four companies named—CareDx, Adaptive Biotechnologies, Enliven Therapeutics, and Amylyx Pharmaceuticals—were also singled out for having recently delivered big gains and harboring significant near-term catalysts. Although the publisher’s full commentary on these stocks was truncated in the source material, their inclusion suggests that each has operational milestones that could materially impact share prices. CareDx, a transplant diagnostics firm, may be approaching new product launches or reimbursement decisions that build on its leadership in donor-derived cell-free DNA testing. Adaptive Biotechnologies, a pioneer in immune-driven medicine, likely has ongoing or upcoming data readouts for its T-cell receptor-based tests in minimal residual disease monitoring and autoimmune conditions. Enliven Therapeutics, which focuses on next-generation kinase inhibitors for cancer, is probably advancing through dose expansion or pivotal trial starts. And Amylyx Pharmaceuticals, known for its ALS therapy, may have pipeline updates in neurodegenerative diseases such as Wolfram syndrome or other disorders. The absence of detailed specifics in the source article forces investors to monitor these names independently, but the overarching theme is unmistakable: momentum in biotech is often sustained by a cadence of catalysts, and these five companies exemplify that pattern.